Afrikaans
Akan
Albanian
Amharic
Arabic
Armenian
Azerbaijani
Basque
Belarusian
Bemba
Bengali
Bihari
Bosnian
Breton
Bulgarian
Cambodian
Catalan
Cebuano
Cherokee
Chichewa
Chinese (Simplified)
Chinese (Traditional)
Corsican
Croatian
Czech
Danish
Dutch
English
Esperanto
Estonian
Ewe
Faroese
Filipino
Finnish
French
Frisian
Ga
Galician
Georgian
German
Guarani
Gujarati
Haitian Creole
Hausa
Hawaiian
Hebrew
Hindi
Hmong
Hungarian
Icelandic
Igbo
Indonesian
Interlingua
Irish
Italian
Japanese
Javanese
Kannada
Kazakh
Kinyarwanda
Kirundi
Kongo
Korean
Krio (Sierra Leone)
Kurdish
Kurdish (Soranî)
Kyrgyz
Laothian
Latin
Latvian
Lingala
Lithuanian
Lozi
Luganda
Luo
Luxembourgish
Macedonian
Malagasy
Malay
Malayalam
Maltese
Maori
Marathi
Mauritian Creole
Moldavian
Mongolian
Myanmar (Burmese)
Montenegrin
Nepali
Nigerian Pidgin
Northern Sotho
Norwegian
Norwegian (Nynorsk)
Occitan
Oriya
Oromo
Pashto
Persian
Polish
Portuguese (Brazil)
Portuguese (Portugal)
Punjabi
Quechua
Romanian
Romansh
Runyakitara
Russian
Samoan
Scots Gaelic
Serbian
Serbo-Croatian
Sesotho
Setswana
Seychellois Creole
Shona
Sindhi
Sinhalese
Slovak
Slovenian
Somali
Spanish
Spanish (Latin American)
Sundanese
Swahili
Swedish
Tajik
Tamil
Tatar
Telugu
Thai
Tigrinya
Tonga
Tshiluba
Tumbuka
Turkish
Turkmen
Twi
Uighur
Ukrainian
Urdu
Uzbek
Vietnamese
Welsh
Wolof
Xhosa
Yiddish
Yoruba
Zulu
[narrator] On "Tomorrow's World Today," we explore the cutting edge
advances that are shaping four different worlds.
The world of inspiration, where the wonders
of the natural world amaze and inspire us.
The world of creation, where ideas come to life
from traditional arts.
The world of innovation, where ideas and inventions
move us all forward.
The world of production, where innovations are mass produced
to improve our lives.
From Inventionland, World Headquarters,
here's your host, George Davison.
Did you know that your body's constantly writing
a hidden history?
Every day, billions of your cells are shedding
tiny fragments of their DNA into your bloodstream.
It's a molecular code of who you are.
Welcome to "Tomorrow's World Today."
Now, for centuries, this code was invisible to us,
a secret written in a language we simply couldn't see.
The quest to see cancer, well, it all began
in ancient Egypt,
where Edwin Smith Papyrus first described
bulging tumors nearly 5,000 years ago.
But for most of history, we could only find cancer
once it was large enough to feel.
Now that changed in 1928, when Dr. Papanikoláou,
he developed the Pap smear to detect cancer
at the cellular level for the first time.
And he proved that if we could see the change early enough,
we could change the outcome.
Now by the 1960s, imaging techniques
such as mammography, well, it allowed us
to see what the human eye couldn't see.
But even then, we were looking for masses.
The real turning point, it arrived when we stopped
looking for the lump and started looking
for the signal.
We realized that cancer actually leaves microscopic
fingerprints in our blood long before a physical mass
ever appears.
Now today, we're moving beyond just scanning the body.
We're sequencing our survival.
We're entering an era where a simple blood draw can reveal
the earliest signals of many types of cancer.
So I wanna learn more about this.
And I'm gonna send Greg to the World of Innovation
in Madison, Wisconsin, to show us
the latest advancements in cancer screening.
♪♪
For decades, one of the primary goals of modern medicine
has been to find a cure for cancer.
While there are many different types of cancer,
what they have in common is that very often
successful treatment comes down to one thing, early detection.
And that's why we're here in Madison, Wisconsin,
to meet with the makers of the Cancerguard test.
And together, we'll explore how they're helping to win
the battle against this disease today and in tomorrow's world.
I sat down with Dr. Beer, Chief Medical Officer
for Multi-Cancer Early Detection at Abbott Cancer Diagnostics,
to explore their blood test, which uses DNA biomarkers
to screen for multiple cancers.
Dr. Beer, tell me about what was the impetus for developing
Cancerguard as a test? What was the need for that?
Well, first of all, we know that when we detect
cancers earlier, people have better outcomes,
a higher probability of curative therapy,
less aggressive treatment necessary.
But today, we only screen for four or five common cancers.
And so about 70% of cancer diagnoses
and 70% of cancer deaths are due to cancers that
we don't have any screening tests for.
That's the reason for developing Cancerguard.
Why did it take so long for us to get to this point?
I mean, you know, there's been so much advancement
in cancer care and oncology.
Why did it take this long to get to this point?
Well, for a long time, the field has focused
on developing single cancer screening tests.
And it takes a decade or two to develop the evidence necessary
to prove that these tests are useful.
But focusing one cancer at a time has an inherent
limitation once you get beyond the most common cancers.
And so it's really been impossible to address
those other cancers like pancreatic cancer,
ovarian cancer, and others
until we developed a multi cancer approach
like Cancerguard.
Right, so multi cancer early detection is really what
Cancerguard is all about. But the story
that it's looking for is actually in the blood.
Yeah, so it turns out that cancers secrete
into the bloodstream what we call biomarkers,
or minute concentrations of cancer DNA
or cancer associated proteins.
Those are the kinds of markers that we look for in the blood
with Cancerguard, and we put together
these multiple measurements into a single algorithm
that tells us whether we should be concerned
about a cancer or not.
-OK, so the blood basically tells the story in this. -Yes.
So a lot of folks would probably compare this a bit
with Cologuard, which is
an at-home screening for colon cancer.
But rather than making a sample at home and sending it in,
this is a -- this is a blood draw.
Yes, I think there are some similarities and lessons
from Cologuard, but also some differences.
Cologuard proved to us that we can use,
um, uh...
the detection of DNA biomarkers to pick up a cancer early.
That's a critical advance.
But the difference is that Cancerguard is a blood test.
So it's not an at-home stool test like Cologuard.
You can get your blood drawn at home
with what we call mobile phlebotomy,
or a person who can draw your blood,
they can come to your home.
You can also get that at a brick and mortar laboratory
or in a doctor's clinic or a hospital.
Great, well,
now a Cancerguard itself, so it's --
it's not a diagnosis.
It doesn't necessarily mean that you have cancer, but it is
a screening that will let you know that you should talk
to your doctor further. -Yeah.
So just like other screening tests that you can think about,
Cologuard, we've already talked about,
mammography and so on and so forth,
Cancerguard gives a signal
um, that triggers us to
uh...
look and determine whether a cancer's present or not.
So most of the time, one can expect a negative result,
meaning no further workup is necessary.
But when we get a positive result that is not
a diagnosis of cancer,
it is a signal that we need to do more to rule in or rule out
the presence of cancer.
Right, so mammographies and things like this,
this is not to take that place. -No.
Mammography, colorectal cancer screening, lung cancer
screening, if you're a smoker, cervical cancer screening,
perhaps PSA testing are really well established,
proven screening approaches.
And Cancerguard is designed to work in concert with those,
not as a replacement. -Great.
Well, doctor, thank you very much.
Don't go too far, we're gonna catch up again later.
My pleasure. Thank you so much.
♪♪
[Greg] I'm going to meet with Dr. Michelle Beidelschies,
Director of Medical Affairs for Multi-Cancer Early Detection,
to discuss a positive result and care navigation services.
So, doctor, who are the folks that the Cancerguard test
is really designed for?
Yeah, the test is indicated for individuals,
adults, who have not had a prior history of cancer
in the previous three years.
Now, certainly there are risk factors, if you will,
or perhaps even a family history that someone might have.
They may have known genetic predisposition or may not know
their genetic predisposition, but the Cancerguard test
could be right for them.
So a family history isn't necessarily an indicator
of genetic predisposition, as you say.
That's -- that's correct.
A lot of people don't know their family history,
but certainly they have relatives and know
of different cancers that have popped up in their family,
so this technology might be valuable to them.
Right, right. Well, let's kind of walk
through the test itself.
Take me through the process.
So as it relates to getting the Cancerguard test,
it can be ordered by your provider
or you can request it to be ordered through our website.
So it still needs to be
prescribed by a medical provider?
Yes, it needs to be prescribed by a medical provider.
And once that's done, then you get a kit
and you're able to take it to a blood draw station.
We actually have phlebotomists that can come to your home
and actually collect the blood.
And so once that's done, the blood then goes
to the laboratory where the assays are performed,
and then a patient is given a final report.
♪♪
OK, well, let's talk about those results.
What if you get a negative result?
So the negative result is actually quite valuable, right?
That means that there's no cancer signal detected,
which is a great thing.
Now, certainly, there might be situations where
there is a cancer, but the test missed it.
But overall, a no cancer signal detected is a very good thing.
Well, let's look at the opposite as well.
How about if a patient gets a positive result?
Yeah, so if there is a positive result,
we call that a cancer signal detected.
And what that means is that our assay picked up some
of the biological biomarkers in the blood.
Now, this certainly is not diagnostic.
It doesn't necessarily mean you have cancer.
What it means is the assay picked up a signal,
and so it requires further workup to what we call localize
and potentially diagnose a cancer if it in fact exists.
[Greg] Excellent, well,
let's talk a little bit about the blood itself.
What are the things that the Cancerguard test is
looking for in that sample?
So the Cancerguard test is the only test that looks
at a multi-biomarker class approach.
And what that means is we evaluate
two different biomarker classes.
That would be circulating tumor DNA as well as proteins.
And those two biomarker classes are important because this is
what is released from the cancer tumor cells.
And we're able to pick that up as part of our assay.
And what we do is we look at each of those biomarker
classes individually, and then we combine them
together through an algorithm and are able to provide
that result of no cancer signal detected
or cancer signal detected.
So once that positive result comes back,
what other sorts of supports are available
through the Cancerguard network?
Yeah, once you do get a positive result,
we provide care navigation, not just to the patient
but also to the provider.
And so from the provider perspective, we're available
to answer any questions that they might have,
provide educational support.
We have a fantastic field medical team
and the laboratory director that's there
to answer questions.
And then from a patient perspective,
we have a dedicated team of individuals that are able
to support the patient along their journey, whether that's
talking to their insurance company, helping them to get
to imaging needed to localize and diagnose
that potential cancer.
But I think one of the most important assets that we offer
for the patients and support is
the patient reimbursement program
for imaging services.
So we offer up to $6,000 to the patient
for non-covered imaging costs. -Wow, that's really excellent!
Well, doctor, thank you very much.
Thank you.
♪♪
[Greg] I reconnected with Dr. Tom Beer to examine the significant
economic impact of early cancer detection.
Doctor, let's talk about the economic advantage
of a -- of an early detection versus the long-term impact
of a later diagnosis.
Yeah, so we know that treatment of earlier stages
of cancer is not only more straightforward
and often more successful,
but it is usually much less expensive
than treatment for advanced cancer,
especially when the cancer gets to stage four,
where often multiple treatments are required
with very expensive agents.
Now, Cancerguard currently is still a self-pay test,
um, but if you maybe have concerns over family history
or maybe where you were working, it still seems as though
it would be an investment in your long-term health.
Yes, as you mentioned, Cancerguard is available today
as a self-pay test.
Our long-term goal is to have the test be FDA-approved,
widely available, and reimbursed by insurance
so that everyone can access it.
In the meantime, we wanted to make the test available
as soon as possible to as many people as we can.
And we're also learning a great deal by having the test
available to people today. -Excellent.
Well, doctor, again, thank you very much.
Thank you.
[Greg] I had a chance to meet with Allison Barry,
a Cancerguard employee, to discuss her journey
after receiving a positive test result.
-Hi, Allison. -Hi, Greg.
-How are you? -I'm great.
-How are you? -I'm doing well.
So, Allison, you work for the company, but you also have
a really personal connection to the Cancerguard test.
-Tell me about that. -Sure.
So I've been working for the company
for a little over five years.
What brought me to the company was the Cancerguard test
when it was still in development.
I work on communications for the company
and for the test.
So the first day it was available,
I was really excited to order it.
I wanted to know what it was like, the whole process,
so I could go out and talk about it confidently.
I never expected the result to be a positive,
but in fact, it was. -Wow.
What's the next step after you get that positive result?
Sure. So a positive test result
doesn't automatically mean that you have cancer.
You need to follow up with your primary care physician.
And that's exactly what I did a few days later.
And at that appointment, my physician ordered
a set of three CT scans, one of my neck, one of my chest,
and one of my abdomen and my pelvis.
When those test results came back,
they revealed a 22-centimeter likely malignant tumor
on my right ovary.
Wow. So did you have to
immediately undergo surgery? -I did.
I was scheduled for surgery pretty quickly afterward,
and it was a five-hour surgery.
They were able to remove the entire tumor.
They did dozens of biopsies. Those all came back negative.
And the final pathology revealed a stage one
ovarian cancer. -Wow.
So did you have to do any follow-up chemo,
radiation, anything like that? -I did not.
And I was very fortunate in the fact that
my specific type of ovarian cancer is very rare,
and it's known to be resistant to chemotherapy.
So finding it in an early stage was really, really important
for me to just move forward with my life.
Right, it would have been much more difficult
to deal with later on. -Very much so.
Wow. OK.
Well, so now you're doing well. You're cancer-free.
-I am. -Excellent.
Excellent. Well, show me how you signed up
for the test and how somebody can just get online
and take care of this for themselves.
Sure. Yeah.
You just go right to cancerguard.com.
It's really easy.
You can go on a computer, you can go on your phone,
and you just hit, "Request online."
You answer a few questions, you put in your information,
and it goes to a medical professional to review.
And you can also go see your primary care physician
at your next appointment, request the test there.
-So it's really easy. -Excellent.
So it's like signing up for just about
any other website that you find.
-It sure is, yeah. -All right, excellent, well,
Allison, thank you very much. -Thank you so much, Greg.
[George] I'm meeting with David Harding, Senior Vice President
of Pipeline Product Management, to talk about the future
of cancer screenings.
Hi, David. Welcome to Inventionland.
Thank you very much.
It's a pleasure to be here, George.
You know, I'm excited for you to be here
because this field of cancer
and trying to identify cancer earlier,
that's of interest to me. And I --
That, like, even the whole history of cancer, you know,
back in the old days, you'd see a lump,
maybe touch that and know you have a problem.
And then, of course, innovation happens
and screening was invented, and mammography became a thing.
And now we've moved again into the future where now
we're looking at the blood and it's starting to indicate
that we may or may not have a cancer, but being able
to find that out so early,
that's a really important piece of work.
Can you talk a little bit about it?
Yeah, I mean, it really is interesting to look at the arc
of how cancer screening has evolved over the decades.
And I think we're at a fundamental transition point
here where now that we can understand molecularly what's
happening in the blood and get these very small, tiny signals
from cancers that may be in your body,
we have the ability to really revolutionize cancer screening
and change it in a way that's fundamentally different.
That's exciting to me.
And the way I'd like to think about it is it's like
all innovations and technologies.
When they first come out, you know, they can be a little
unnerving, you know, "Should I, should I give that a try?"
And, uh, so I was thinking about how do we get across
to the audience out there that this could be a better way of,
you know, identifying whether or not you may have
cancer, right? -Yeah.
I think it's important to acknowledge that, yes,
there is a certain amount of anxiety that comes
with any kind of medical testing, but then I think
you need to think about the impact
of what this might do.
All of us have friends and family members who
have been detected with late stage cancer.
And we all know the pain and suffering and cost
that comes with that... -[George] Mm-hmm.
...to not only the patient, but also to their family.
And I think you need to really understand that detecting
that cancer early makes a massive difference
in the life of that patient and the family.
And so I think we need to think about what's possible, right?
And be courageous and move forward
with this kind of testing that can fundamentally
expand the number of cancers that we can detect
and potentially detect them much earlier
when there's a chance to treat them much more effectively.
So that's what gives me the courage to move forward
and what I would encourage everybody to think about
as they adopt this new technology.
Yeah, and so trying to get the general population
to understand that this is a big advance
and that they should take a chance
and go get this done.
But I think there's another, there's always like a step
in the process of getting innovations
and technology to market.
So how do we get doctors informed so that,
you know, they're more apt to adopt what's going on here?
I mean, what kind of things would you run into
in the field?
Yeah, typically what I would say is, doctor, have you ever
had a patient come in who was worried about something like,
you know, a pancreatic cancer or ovarian cancer,
these very aggressive, you know, very high-mortality cancers,
have they ever asked you, like, what can I do?
I'm doing all my other screening tests.
What can I do to, you know,
maybe detect those cancers earlier?
And now we have a solution for that, right?
It's a very revolutionary solution that really broadens
the tools that you have, doc, available... -[George] Right.
...to help screen that patient.
And I think most doctors really understand that
very intuitively. -Yeah.
I mean, it's great.
You guys are chasing a noble cause.
David, thanks for everything
you and your team have been working on.
Well, everybody, that's another edition
of "Tomorrow's World Today." And we'll see you next time.
So, David, I've got this new stuff
we're working on in the lab.
And remember, Tomorrow's World is where inspiration
and creation drive innovation and production.
See you next time.
Can't find what you're looking for?
Get subtitles in any language from opensubtitles.com, and translate them here.